welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
-
Christina Laukaitis, MD, PhDDr. Laukaitis' interest is to understan...
-
Targeted Therapy for Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Fam...Cancer genetics has rapidly evolved in t...
-
Riccardo Fodde, PhDRiccardo Fodde is also professor of Canc...
-
Aspirin and Familial Adenomatous Polyposis: Coming Full CircleThis perspective discusses the clinical ...
-
Detection of Epithelial Apoptosis in Pelvic Ileal Pouches for Ulcerative Colitis and Familial Adenomatous PolyposisBACKGROUND : Ileal pouch-anal anastomosi...
-
Fokko M. NagengastTeacher at Wageningen University, Divisi...
-
Serum Nutrients and Habitual Dietary Intake in Colectomized FAP Patients in NorwayBACKGROUND : Patients with familial aden...